BACKGROUND: Side effects emerging after COVID-19 vaccines may adversely impact public confidence in vaccines. Therefore, this study was designed to explore the short-term side effects of COVID-19 vaccines as a part of the COVID-19 Vaccines Safety Tracking (CoVaST) study. METHODS: A cross-sectional survey-based study was carried out to collect data from healthcare workers (HCWs) in Saudi Arabia. The study was initiated between June and December 2021. A validated questionnaire was used in this study consisting of four categories, including demographic characteristics and medical anamnesis of the participants, COVID-19-associated anamnesis, and side effects of vaccine uptake. RESULTS: The study included 1039 participants, of which 70.2% were females, and their median age was 34. About 82.9% and 52.3% of the participants reported a minimum of both one local and systemic side effect, respectively. Females, young participants (≤34 years old), and non-obese participants had more potential to disclose post-vaccination side effects than their counterparts. Heterologous schedules and viral vector-based vaccines were linked with a greater rate of systemic side effects, whereas homologous vaccination schedules and mRNA-based vaccines were linked with a greater rate of local side effects. CONCLUSION: Future studies on COVID-19 vaccines should focus on the role of BMI, previous infection, and vaccination schedule in terms of vaccine safety and reactogenicity.

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Faculty of Medicine Masaryk University 625 00 Brno Czech Republic

Department of Family Medicine King Fahad Specialist Hospital Dammam 32253 Saudi Arabia

Department of Infectious Diseases King Fahad Specialist Hospital Dammam 32253 Saudi Arabia

Institute of Health Information and Statistics of the Czech Republic 128 01 Prague Czech Republic

Zobrazit více v PubMed

Siyal F.J., Shaikh Z.A., Ahmed S.Z., Shahid M.A., Agha F., Khoso M., Unar A.A., Unar K., Saleem R., Shahani M.P. Anxiety among COVID-19 Physicians during the Pandemic in the Health Care Center of the Rural Region. Arch. Pharm. Pract. 2020;11:91–93.

Fadel H.H., Ahmed M.A.E.-R. A Combination of Immunotherapies and Micronutrients May Relieve the Severe Illness in COVID-19 Patients: Review Article. Int. J. Pharm. Phytopharm. Res. 2020;10:8–21.

World Health Organization (WHO) Advice for the Public. [(accessed on 28 October 2022)]. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public.

Centers for Disease Control and Prevention (CDC) CDC Streamlines COVID-19 Guidance to Help the Public Better Protect Themselves and Understand Their Risk. [(accessed on 28 October 2022)]; Available online: https://www.cdc.gov/media/releases/2022/p0811-covid-guidance.html.

Orenstein W.A., Ahmed R. Simply Put: Vaccination Saves Lives. Proc. Natl. Acad. Sci. USA. 2017;114:4031–4033. doi: 10.1073/pnas.1704507114. PubMed DOI PMC

Davis T.C., Fredrickson D.D., Arnold C.L., Cross J.T., Humiston S.G., Green K.W., Bocchini J.A.J. Childhood Vaccine Risk/Benefit Communication in Private Practice Office Settings: A National Survey. Pediatrics. 2001;107:E17. doi: 10.1542/peds.107.2.e17. PubMed DOI

Bond L., Nolan T., Pattison P., Carlin J. Vaccine Preventable Diseases and Immunisations: A Qualitative Study of Mothers? Perceptions of Severity, Susceptibility, Benefits and Barriers. Aust. N. Z. J. Public Health. 1998;22:441–446. doi: 10.1111/j.1467-842X.1998.tb01411.x. PubMed DOI

MacDonald N.E., Eskola J., Liang X., Chaudhuri M., Dube E., Gellin B., Goldstein S., Larson H., Manzo M.L., Reingold A., et al. Vaccine Hesitancy: Definition, Scope and Determinants. Vaccine. 2015;33:4161–4164. doi: 10.1016/j.vaccine.2015.04.036. PubMed DOI

Alabdulla M., Reagu S.M., Al-Khal A., Elzain M., Jones R.M. COVID-19 Vaccine Hesitancy and Attitudes in Qatar: A National Cross-Sectional Survey of a Migrant-Majority Population. Influenza Other Respir. Viruses. 2021;15:361–370. doi: 10.1111/irv.12847. PubMed DOI PMC

Alibrahim J., Awad A. COVID-19 Vaccine Hesitancy among the Public in Kuwait: A Cross-Sectional Survey. Int. J. Environ. Res. Public Health. 2021;18:8836. doi: 10.3390/ijerph18168836. PubMed DOI PMC

World Health Organization (WHO) Ten Threats to Global Health in 2019. [(accessed on 7 May 2021)]. Available online: https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019.

Kaur S.P., Gupta V. COVID-19 Vaccine: A Comprehensive Status Report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. PubMed DOI PMC

Dal-Ré R., Caplan A.L., Gluud C., Porcher R. Ethical and Scientific Considerations Regarding the Early Approval and Deployment of a COVID-19 Vaccine. Ann. Intern. Med. 2021;174:258–260. doi: 10.7326/M20-7357. PubMed DOI PMC

Tumban E. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval. Viruses. 2021;13:54. doi: 10.3390/v13010054. PubMed DOI PMC

Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and Efficacy of the ChAdOx1 NCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. PubMed DOI PMC

Centres for Diseases Control and Prevention (CDC) Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine. Centres for Diseases Control and Prevention; Atlanta, GA, USA: 2021.

Ministry of Health—Kingdom of Saudi Arabia (MOH-KSA) COVID-19 Vaccine. [(accessed on 1 August 2022)]; Available online: https://www.moh.gov.sa/en/awarenessplateform/VariousTopics/Pages/COVID-19Vaccine.aspx.

Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 MRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. PubMed DOI PMC

Carli G., Nichele I., Ruggeri M., Barra S., Tosetto A. Deep Vein Thrombosis (DVT) Occurring Shortly after the Second Dose of MRNA SARS-CoV-2 Vaccine. Intern. Emerg. Med. 2021;16:803–804. doi: 10.1007/s11739-021-02685-0. PubMed DOI PMC

Harvard Humanitarian Initiative. Welcome to KoBoToolbox. [(accessed on 4 January 2022)]. Available online: https://support.kobotoolbox.org/welcome.html.

El-Shitany N.A., Harakeh S., Badr-Eldin S.M., Bagher A.M., Eid B.G., Almukadi H.S., Alghamdi B.S., Alahmadi A.A., Hassan N.A., Sindi N., et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine among Saudi Residents: A Retrospective Cross-Sectional Study. Int. J. Gen. Med. 2021;14:1389–1401. doi: 10.2147/IJGM.S310497. PubMed DOI PMC

Ahsan W., Syed N.K., Alsraeya A.A., Alhazmi H.A., Najmi A., Al Bratty M., Javed S., Makeen H.A., Meraya A.M., Albarraq A.A., et al. Post-Vaccination Survey for Monitoring the Side Effects Associated with COVID-19 Vaccines among Healthcare Professionals of Jazan Province, Saudi Arabia. Saudi Med. J. 2021;42:1341–1352. doi: 10.15537/smj.2021.42.12.20210576. PubMed DOI PMC

Darraj M.A., Al-Mekhlafi H.M. Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia. Vaccines. 2022;10:223. doi: 10.3390/vaccines10020223. PubMed DOI PMC

Mohammed R.A., Garout R.M., Wahid S., Ayub F., ZinAlddin L.M.F., Sultan I. A Survey on the Side Effects of Pfizer/BioNTech COVID-19 Vaccine among Vaccinated Adults in Saudi Arabia. Cureus. 2021;13:e19222. doi: 10.7759/cureus.19222. PubMed DOI PMC

Alghamdi A., Ibrahim A., Almutairi R., Joseph M., Alghamdi G., Alhamza A. A Cross-Sectional Survey of Side Effects after COVID-19 Vaccination in Saudi Arabia: Male versus Female Outcomes. J. Adv. Pharm. Educ. Res. 2021;11:51–56. doi: 10.51847/bCwca2qGfP. DOI

Alzarea A.I., Khan Y.H., Alatawi A.D., Alanazi A.S., Alzarea S.I., Butt M.H., Almalki Z.S., Alahmari A.K., Mallhi T.H., Alzarea A.I., et al. Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines. 2022;10:924. doi: 10.3390/vaccines10060924. PubMed DOI PMC

Alamer E., Alhazmi A., Qasir N.A., Alamer R., Areeshi H., Gohal G., Qadri M., Hashem A.M., Algaissi A. Side Effects of COVID-19 Pfizer-BioNTech MRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia. Vaccines. 2021;9:1297. doi: 10.3390/vaccines9111297. PubMed DOI PMC

Riad A., Pokorná A., Attia S., Klugarová J., Koščík M., Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med. 2021;10:1428. doi: 10.3390/jcm10071428. PubMed DOI PMC

Riad A., Hocková B., Kantorová L., Slávik R., Spurná L., Stebel A., Havriľak M., Klugar M. Side Effects of MRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia. Pharmaceuticals. 2021;14:873. doi: 10.3390/ph14090873. PubMed DOI PMC

Klugar M., Riad A., Mekhemar M., Conrad J., Buchbender M., Howaldt H.-P., Attia S. Side Effects of MRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021;10:752. doi: 10.3390/biology10080752. PubMed DOI PMC

Yesuf E.A., Riad A., Sofi-Mahmudi A., Sudhakar M., Mekonnen A., Endalkachew S., Mama F., Muhidin S., Ayele B., Yahya M., et al. Self-Reported Side Effects of the Oxford AstraZeneca COVID-19 Vaccine among Healthcare Workers in Ethiopia, Africa: A Cross-Sectional Study. Front. Public Health. 2022;10:937794. doi: 10.3389/fpubh.2022.937794. PubMed DOI PMC

Riad A., Sağıroğlu D., Üstün B., Pokorná A., Klugarová J., Attia S., Klugar M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J. Clin. Med. 2021;10:2629. doi: 10.3390/jcm10122629. PubMed DOI PMC

Dziedzic A., Riad A., Attia S., Klugar M., Tanasiewicz M. Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe. J. Clin. Med. 2021;10:5338. doi: 10.3390/jcm10225338. PubMed DOI PMC

Lounis M., Rais M.A., Bencherit D., Aouissi H.A., Oudjedi A., Klugarová J., Pokorná A., Klugar M., Riad A. Side Effects of COVID-19 Inactivated Virus versus Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers. Front. Public Health. 2022;10:896343. doi: 10.3389/fpubh.2022.896343. PubMed DOI PMC

Green M.S., Peer V., Magid A., Hagani N., Anis E., Nitzan D. Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine. Vaccines. 2022;10:233. doi: 10.3390/vaccines10020233. PubMed DOI PMC

Green M.S., Nitzan D., Schwartz N., Niv Y., Peer V. Sex Differences in the Case-Fatality Rates for COVID-19—A Comparison of the Age-Related Differences and Consistency over Seven Countries. PLoS ONE. 2021;16:e0250523. doi: 10.1371/journal.pone.0250523. PubMed DOI PMC

Jacobsen H., Klein S.L. Sex Differences in Immunity to Viral Infections. Front. Immunol. 2021;12:3483. doi: 10.3389/fimmu.2021.720952. PubMed DOI PMC

Klein S.L., Pekosz A. Sex-Based Biology and the Rational Design of Influenza Vaccination Strategies. J. Infect. Dis. 2014;209:S114. doi: 10.1093/infdis/jiu066. PubMed DOI PMC

Flanagan K.L., Fink A.L., Plebanski M., Klein S.L. Sex and Gender Differences in the Outcomes of Vaccination over the Life Course. Annu. Rev. Cell Dev. Biol. 2017;33:577–599. doi: 10.1146/annurev-cellbio-100616-060718. PubMed DOI

Chen J., Cai Y., Chen Y., Williams A.P., Gao Y., Zeng J. Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-analysis of Clinical Trials. Vaccines. 2021;9:939. doi: 10.3390/vaccines9080939. PubMed DOI PMC

Walsh E.E., Frenck R.W., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906. PubMed DOI PMC

Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., Enama M.E., Nelson S., Nason M., Gu W., et al. A West Nile Virus DNA Vaccine Utilising a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. J. Infect. Dis. 2011;203:1396–1404. doi: 10.1093/infdis/jir054. PubMed DOI PMC

Iguacel I., Maldonado A.L., Luna Ruiz-Cabello A., Casaus M., Moreno L.A., Martínez-Jarreta B., Apostolopoulos V., Homaira N. Association between COVID-19 Vaccine Side Effects and Body Mass Index in Spain. Vaccines. 2021;9:1321. doi: 10.3390/vaccines9111321. PubMed DOI PMC

Zare H., Rezapour H., Mahmoodzadeh S., Fereidouni M. Prevalence of COVID-19 Vaccines (Sputnik V, AZD-1222, and Covaxin) Side Effects among Healthcare Workers in Birjand City, Iran. Int. Immunopharmacol. 2021;101:108351. doi: 10.1016/j.intimp.2021.108351. PubMed DOI PMC

Pellini R., Venuti A., Pimpinelli F., Abril E., Blandino G., Campo F., Conti L., de Virgilio A., de Marco F., Gino Di Domenico E., et al. Obesity May Hamper SARS-CoV-2 Vaccine Immunogenicity. medRxiv. 2021 doi: 10.1101/2021.02.24.21251664. Preprint . PubMed DOI

Andrzejczak-Grządko S., Czudy Z., Donderska M. Side Effects after COVID-19 Vaccinations among Residents of Poland. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4418–4421. doi: 10.26355/EURREV_202106_26153. PubMed DOI

Rzymski P., Sikora D., Zeyland J., Poniedziałek B., Kiedik D., Falfushynska H., Fal A. Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. Vaccines. 2022;10:754. doi: 10.3390/vaccines10050754. PubMed DOI PMC

Costa Clemens S.A., Weckx L., Clemens R., Almeida Mendes A.V., Ramos Souza A., Silveira M.B.V., da Guarda S.N.F., de Nobrega M.M., de Moraes Pinto M.I., Gonzalez I.G.S., et al. Heterologous versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses of CoronaVac COVID-19 Vaccine in Brazil (RHH-001): A Phase 4, Non-Inferiority, Single Blind, Randomised Study. Lancet. 2022;399:521–529. doi: 10.1016/S0140-6736(22)00094-0. PubMed DOI PMC

Schmidt T., Klemis V., Schub D., Mihm J., Hielscher F., Marx S., Abu-Omar A., Schneitler S., Becker S.L., Gärtner B.C., et al. Immunogenicity and Reactogenicity of a Heterologous COVID-19 Prime-Boost Vaccination Compared with Homologous Vaccine Regimens. Nat. Med. 2021;27:1530–1535. doi: 10.1038/s41591-021-01464-w. PubMed DOI PMC

Ooi E.E., Dhar A., Petruschke R., Locht C., Buchy P., Low J.G.H. Use of Analgesics/Antipyretics in the Management of Symptoms Associated with COVID-19 Vaccination. NPJ Vaccines. 2022;7:31. doi: 10.1038/s41541-022-00453-5. PubMed DOI PMC

Sah R., Shrestha S., Mehta R., Sah S.K., Raaban A.A., Dharma K., Rodriguez-Morales A.J. AZD1222 (Covishield) Vaccination for COVID-19: Experiences, Challenges, and Solutions in Nepal. Travel. Med. Infect. Dis. 2021;40:101989. doi: 10.1016/j.tmaid.2021.101989. PubMed DOI PMC

Serwaa D., Osei-Boakye F., Nkansah C., Ahiatrogah S., Lamptey E., Abdulai R., Antwi M.H., Wirekoh E.Y., Owusu E., Buckman T.A., et al. Non-Life-Threatening Adverse Reactions from COVID-19 vaccine; a Cross-Sectional Study with Self-Reported Symptoms among Ghanaian Healthcare Workers. Hum. Vaccines Immunother. 2021;17:3881–3886. doi: 10.1080/21645515.2021.1963600. PubMed DOI PMC

Editorial: COVID-19 Vaccines Safety Tracking (CoVaST): Part I